

VYVGART (EFGARTIGIMOD ALFA-FCAB) ORDER SET

P: 877.365.5566 | F: 855.889.2946

A	A Carelon Company		P: 8//.305.5	566 F: 855.889.2946
PATIENT	INFORMATION:	Fax completed form, ins	urance information, and clin	nical documentation to 855.889.2946
Patient Nan	ne:		DOB:	Phone:
Patient Sta	tus: 🗆 New to Therapy	Continuing Therap	y Next Treatment D	ate:
MEDICAL	INFORMATION			
Diagnosis:	□ Myasthenia Gravis □ Myasthenia Gravis □ Chronic inflammato □ Other:	w/acute exacerbatio ory demyelinating po	n (ICD-10: G70.01) Iyneuropathy (ICD-	-10: G61.81)
gMG Classi	fication (if applicable)):		
Patient We	ight: lbs. (rec	quired) Allergies:		
THERAPY	(ORDER			
Vyvgart (l	V)			
_	ts weighing less than 120			
	ts weighing 120kg (264 l	lbs.) or greater Vyvgarl	t 1200mg IV weekly fo	r 4 weeks
	ytrulo (SubQ)			
	1,008mg / 11,200 units s	-	-	
CIDP:	1,008mg / 11,200 units s	ubcutaneously once w	eekly	
None For CIDP	patients (cycle may be e	cycle(s), subsequent cycle	e(s) to start >50 days fro	
Other orde	ers:			
	s: abs to be drawn by:			0 🗌 Other:
 Epinep Diphen NS 0.9^o Home biolog Dispen 	ogic Ana-kit Orders (adult): hrine: >30kg (>66lbs): Epi hydramine: Administer 25-5 % 1000mL IV bolus per prof ic injection Ana-kit (adult): se per protocol EpiPen 0.3 NS 1-20mL pre/post infusio	Pen 0.3mg or compounde 50mg orally OR IV (adult) tocol PRN (adult) 5 5mg IM (2-pack)		
PROVIDE	R INFORMATION			
agent in dealing with Provider Na Provider NP □ Opt out c	th medical and prescription insurance co	ompanies, and to select the preferred :	site of care for the patient.	uthorization and specialty pharmacy designated Date: ct Person:
City:	State	e: <i>Vi</i>	ew our locations here:	
		PARAGONHEALTHC	ARE.COM	

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.





A Carelon Company

PATIENT INFORMATION:

Dationt	Namo
Patient	iname:

DOB:

REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVA	
Include <u>signed</u> and <u>completed</u> order (MD/prescriber to complete page 1)	
Include patient demographic information and insurance information	
Include patient's current medication list	
□ Supporting clinical notes to include any past tried and/or failed therapies, intolerance benefits, or contraindications to conventional therapy	,
☐ Has the patient had a documented contraindication/intolerance or failed trial of conventional therapy (i.e., pyridostigmine, immunosuppressants, corticosteroids, or acetylcholinesterase inhibitors)? ☐ Yes ☐ No If yes, which drug(s)?	
☐ Has the patient required 2 or more courses of plasmapheresis/plasma exchanges and/or intravenous immune globulin for at least 12 months without symptom control? ☐ Yes ☐ No	
Myasthenia Gravis Activities of Daily Living (MG-ADL) Score:	
Does patient have a history of abnormal neuromuscular transmission test demonstrated by single-fiber electromyography (SFEMG) or repetitive nerve stimulation?	
\Box Does the patient have a history of positive anticholinesterase test? \Box Yes \Box No	
Include labs and/or test results to support diagnosis	
anti-AChR antibodies (required for gMG)	
If ordering a subsequent treatment cycle, and patient is new to Paragon, please indicate the start date of the last completed cycle	Э
Other medical necessity:	

Paragon Healthcare will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

Please fax all information to (855) 889-2946 or call (877) 365-5566 for assistance

PARAGONHEALTHCARE.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named address and contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.